MAPT and Alzheimer disease: For the purposes pursued here, we restricted the tau phospho-epitope characterization to monitoring occupancy of pThr231 (AT180) and pSer202/pThr205 (AT8) phospho-acceptor sites, two of several known sites that undergo robust hyperphosphorylation also in AD brains, because we had noted that these phospho-epitopes were most responsive to oAβ exposure in the original report (Jin et al., 2011).